81 Results for "

Nav1.7 Inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (81)

81 Results for "Nav1.7 Inhibitor" in MCE Product Catalog:

Cat. No.: HY-13985
CAS No.: 1355631-24-1
Purity:  99.99%
Nav1.7 inhibitor (compound II), a sulfonamide, is a potent Nav1.7 inhibitor. Nav1.7 inhibitor has the potential for a wide range of disorders, particularly pain, including acute pain, inflammatory pain and/or neuropathic pain .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N6691
CAS No.: 71-62-5
Synonyms: 3-Veratroylveracevine
Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC50 of 18.39 µM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12883
CAS No.: 1235403-62-9
Purity:  99.87%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

PF 05089771 is a potent, orally active and selective arylsulfonamide Nav1.7 inhibitor, with IC50 values of 11 nM, 12 nM, 13 nM, 171 nM and 8 nM for hNav1.7, cynNav1.7, dogNav1.7, ratNav1.7, and musNav1.7, respectively. PF 05089771 is under the study for pain and diabetic neuropathy .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P10234A
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Poneratoxin acetate is the acetate salt form of Poneratoxin (HY-P10234). Poneratoxin acetate is the modulator for voltage-gated sodium channel (NaV, EC50 for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12811
CAS No.: 1235397-05-3
Purity:  99.29%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

PF-04856264 is a potent and selective Nav1.7 inhibitor, with IC50s of 28, 131, 19, and 42 nM for human, mouse, cynomolgus monkey and dog Nav1.7, respectively. PF-04856264 has low potency against the rat Nav1.7 channel. PF-04856264 shows analgesic effect .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-131182
CAS No.: 1450595-86-4
Purity:  99.61%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

DS-1971a is a potent, selective, and orally active NaV1.7 inhibitor, with IC50s of 22.8 and 59.4 nM for hNaV1.7 and mNaV1.7, respectively. DS-1971a exerts analgesic effects .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-100727
CAS No.: 1443373-17-8
Purity:  98.06%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC50 of 0.16 μM for human Nav1.7.
loading...
    loading...
Cat. No.: HY-125079
CAS No.: 1233231-30-5
Purity:  98.33%
Synonyms: ANP-230
DSP-2230 is the orally active inhibitor for voltage-gated sodium channel that inhibits Nav1.7-, Nav1.8-, and Nav1.9-derived sodium currents with IC50s of 7.1 μM, 11.4 μM and 6.7 μM, respectively. DSP-2230 can be used to improve neuropathic pain .
loading...
    loading...
Cat. No.: HY-12796
CAS No.: 934240-30-9
Purity:  99.85%
Synonyms: Vixotrigine; GSK-1014802; CNV1014802
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.
loading...
    loading...
Cat. No.: HY-12796A
CAS No.: 934240-31-0
Purity:  98.94%
Synonyms: Vixotrigine hydrochloride; GSK-1014802 hydrochloride; CNV1014802 hydrochloride
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.
loading...
    loading...
Cat. No.: HY-114237
CAS No.: 1494581-70-2
Purity:  99.69%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

GDC-0276 is a potent, selective, reversible and orally active NaV1.7 inhibitor with an IC50 value of 0.4 nM. GDC-0276 is well tolerated and exhibits a good pharmacokinetic profile. GDC-0276 has the potential for the treatment of pain and to address shortcomings of existing pain medications, such as addiction and off-target side effects .
loading...
    loading...
Cat. No.: HY-16723
CAS No.: 1259933-16-8
Synonyms: TV 45070; XEN402
Funapide (TV 45070; XEN402) is an orally active inhibitor of voltage-gated sodium channels (VGSC) in the peripheral nervous system with IC50 values ??of 84 nM and 54 nM for Nav1.5 and Nav1.7, respectively. Funapide has analgesic effects .
loading...
    loading...
Cat. No.: HY-119934
CAS No.: 1494585-79-3
Purity:  99.65%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

NaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC50 of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5 .
loading...
    loading...
Cat. No.: HY-112279
CAS No.: 1629063-81-5
Purity:  98.15%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

GNE-131 is a potent and selective inhibitor of human sodium channel NaV1.7, with an IC50 of 3 nM.
loading...
    loading...
Cat. No.: HY-139081
CAS No.: 1788063-52-4
Purity:  98.84%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

GDC-0310 is a selective acyl-sulfonamide Nav1.7 inhibitor, with an IC50 of 0.6 nM for hNav1.7 .
loading...
    loading...
Cat. No.: HY-107405
CAS No.: 1211866-85-1
Purity:  99.67%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

TC-N 1752 is a potent and orally active inhibitor of Nav1.7, with IC50s of 0.17 μM, 0.3 μM, 0.4 μM, 1.1 μM and 2.2 μM at hNav1.7, hNav1.3, hNav1.4, hNaV1.5 and rNav1.8, respectively. TC-N 1752 also inhibits tetrodotoxin-sensitive sodium channels. TC-N 1752 shows analgesic efficacy in the Formalin model of pain .
loading...
    loading...
Cat. No.: HY-145169
CAS No.: 2241651-99-8
Purity:  99.83%
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 (IC50=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects .
loading...
    loading...
Cat. No.: HY-19958
CAS No.: 912656-34-9
Target:  

Sodium Channel

Research Areas:  

Neurological Disease

XEN907 is a potent and spirooxindole blocker of NaV1.7, with an IC50 of 3 nM. XEN907 also inhibits CYP3A4 in a recombinant human enzyme assay. XEN907 can be used for the research of pain .
loading...
    loading...
Cat. No.: HY-N1847
CAS No.: 21913-98-4
3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC50 of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels .
loading...
    loading...
Cat. No.: HY-164795
CAS No.: 1849603-79-7
SBI-810 is a blood-brain barrier-permeable NTSR1 modulator. SBI-810 promotes the recruitment of β-arrestin-2 to NTSR1 and antagonizes NTSR1-mediated Gq activation. SBI-810 inhibits excitatory synaptic transmission, NMDA receptor and extracellular signal-regulated kinase (ERK) signaling in spinal nociceptive neurons, reduces surface expression of Nav1.7 and action potential firing in primary sensory neurons, and attenuates C-fiber responses. SBI-810 effectively alleviates acute and chronic pain in various rodent models through peripheral and central modulation. SBI-810 is applicable to research related to multiple pain disorders .
loading...
    loading...